Multicenter Phase II Study of Second-line Cetuximab plus Folinic Acid/5-Fluorouracil/Irinotecan (FOLFIRI) in KRAS Wild-type Metastatic Colorectal Cancer: The FLIER Study

被引：5

作者：

Iwamoto, Shigeyoshi ^{[1
]}

Hazama, Shoichi ^{[2
]}

Kato, Takeshi ^{[3
]}

Miyake, Yasuhiro ^{[4
]}

Fukunaga, Mutsumi ^{[5
]}

Matsuda, Chu ^{[6
]}

Bando, Hiroyuki ^{[7
]}

Sakamoto, Junichi ^{[8
]}

Oba, Koh ^{[9
]}

Mishima, Hideyuki ^{[10
]}

机构：

[1] Kansai Med Univ, Takii Hosp, Dept Surg, Moriguchi, Osaka 5708507, Japan

[2] Yamaguchi Univ, Dept Digest Surg & Surg Oncol, Grad Sch Med, Ube, Yamaguchi 755, Japan

[3] Kansai Rosai Hosp, Dept Surg, Amagasaki, Hyogo, Japan

[4] Nishinomiya Municipal Cent Hosp, Dept Surg, Nishinomiya, Hyogo, Japan

[5] Sakai Municipal Hosp, Dept Surg, Sakai, Osaka, Japan

[6] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan

[7] Ishikawa Prefectural Gen Hosp, Dept Gastrointestinal Surg, Kanazawa, Ishikawa, Japan

[8] Tokai Cent Hosp, Kakamigahara, Japan

[9] Hokkado Univ Hosp, Translat Res & Clin Trial Ctr, Sapporo, Hokkaido, Japan

[10] Aichi Med Univ Hosp, Oncol Ctr, Nagakute, Aichi, Japan

来源：

ANTICANCER RESEARCH | 2014年 / 34卷 / 04期

关键词：

Colorectal cancer; KRAS; FOLFIRI; cetuximab; Japanese; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; MUTATION STATUS; RAS MUTATIONS; OPEN-LABEL; IRINOTECAN; THERAPY; FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: This study was the first multicenter phase II study of cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type mCRC as a second-line treatment in Japan including BRAF and PIK3CA genotyping. Patients and Methods: Tumors of 112 pre-registered patients were genotyped for KRAS, BRAF, and PIK3CA. The primary study end-point was response rate, and secondary end-points were progression-free survival (PFS), overall survival (OS), and safety. Results: Sixty-seven patients (59.8%) were EGFR-positive and KRAS wild-type. The mean age of the enrolled patients (n=60) was 62.6 years (range=37-82 years). The response rate was 31.7% and stable disease was observed in 53.3%. No objective response was observed in patients with BRAF or PIK3CA mutations. The median PFS and OS were 7.4 and 18.2 months, respectively. Grade-3/4 adverse events were leucopenia (26.7%), neutropenia (43.3%), paronychia (10.0%), fissure (10.0%) and acne-like rash (5.0%). Conclusion: Second-line cetuximab plus FOLFIRI was effective and well-tolerated.

引用

页码：1967 / 1973

页数：7

共 50 条

[21] A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer [J].

Cao, Ranhua ;

Zhang, Shuai ;

Ma, Dedong ;

Hu, Likuan .

MEDICAL ONCOLOGY, 2015, 32 (01) :1-5

[22] Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study [J].

Pinto, Carmine ;

Di Fabio, Francesca ;

Rosati, Gerardo ;

Lolli, Ivan R. ;

Ruggeri, Enzo M. ;

Ciuffreda, Libero ;

Ferrari, Daris ;

Lo Re, Giovanni ;

Rosti, Giovanni ;

Tralongo, Paolo ;

Ferrara, Raimondo ;

Alabiso, Oscar ;

Chiara, Silvana ;

Ianniello, Giovanni P. ;

Frassoldati, Antonio ;

Bilancia, Domenico ;

Campanella, Giovanna A. ;

Signorelli, Carlo ;

Racca, Patrizia ;

Benincasa, Elena ;

Stroppolo, Maria Elena ;

Di Costanzo, Francesco .

CANCER MEDICINE, 2016, 5 (11) :3272-3281

[23] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [J].

Kohei Shitara ;

Satoshi Yuki ;

Motoki Yoshida ;

Daisuke Takahari ;

Setsuo Utsunomiya ;

Tomoya Yokota ;

Yozo Sato ;

Yoshitaka Inaba ;

Masahiro Tajika ;

Hiroki Kawai ;

Hidekazu Yamaura ;

Mina Kato ;

Kentaro Yamazaki ;

Yoshito Komatsu ;

Kei Muro .

Investigational New Drugs, 2012, 30 :787-793

[24] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines [J].

Shitara, Kohei ;

Yuki, Satoshi ;

Yoshida, Motoki ;

Takahari, Daisuke ;

Utsunomiya, Setsuo ;

Yokota, Tomoya ;

Sato, Yozo ;

Inaba, Yoshitaka ;

Tajika, Masahiro ;

Kawai, Hiroki ;

Yamaura, Hidekazu ;

Kato, Mina ;

Yamazaki, Kentaro ;

Komatsu, Yoshito ;

Muro, Kei .

INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) :787-793

[25] Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G) [J].

Sakai, Daisuke ;

Taniguchi, Hiroya ;

Sugimoto, Naotoshi ;

Tamura, Takao ;

Nishina, Tomohiro ;

Hara, Hiroki ;

Esaki, Taito ;

Denda, Tadamichi ;

Sakamoto, Takeshi ;

Okuda, Hiroyuki ;

Satoh, Taroh ;

Tsushima, Takahiro ;

Makiyama, Akitaka ;

Tsuda, Takashi ;

Hosokawa, Ayumu ;

Kuramochi, Hidekazu ;

Tokunaga, Shinya ;

Moriwaki, Toshikazu ;

Yasui, Hisateru ;

Ishida, Hiroyasu ;

Tsuji, Akihito ;

Otsu, Satoshi ;

Shimokawa, Hozumi ;

Baba, Eishi ;

Sato, Mikio ;

Matsumoto, Shigemi ;

Ozaki, Yukinori ;

Shinozaki, Katsunori ;

Tamagawa, Hiroshi ;

Goto, Masahiro ;

Kadowaki, Shigenori ;

Fujii, Hirofumi ;

Koh, Yasuhiro ;

Yamazaki, Kentaro ;

Hironaka, Shuichi ;

Kishimoto, Junji ;

Boku, Narikazu ;

Hyodo, Ichinosuke ;

Muro, Kei .

EUROPEAN JOURNAL OF CANCER, 2020, 135 :11-21

[26] Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study) [J].

Naoki Nagata ;

Hiromichi Maeda ;

Keiichiro Ishibashi ;

Keiji Hirata ;

Akitaka Makiyama ;

Shigeyoshi Iwamoto ;

Hiroyoshi Takemoto ;

Mitsunobu Imasato ;

Yoichiro Yoshida ;

Yoshinori Munemoto ;

Chihiro Tanaka ;

Yoshitaka Morita ;

Yoshihiro Hotta ;

Atsushi Toyofuku ;

Takeshi Nagasaka ;

Satoshi Morita ;

Junichi Sakamoto ;

Hideyuki Mishima .

Medical Oncology, 2019, 36

[27] Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study [J].

Eric François ;

Jean-François Berdah ;

Emmanuel Chamorey ;

Gérard Lesbats ;

Eric Teissier ;

Jean-François Codoul ;

Jean-Luc Badetti ;

Christophe Hébert ;

Véronique Mari .

Cancer Chemotherapy and Pharmacology, 2008, 62 :931-936

[28] Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer:: a Phase II study [J].

Francois, Eric ;

Berdah, Jean-Francois ;

Chamorey, Emmanuel ;

Lesbats, Gerard ;

Teissier, Eric ;

Codoul, Jean-Francois ;

Badetti, Jean-Luc ;

Hebert, Christophe ;

Mari, Veronique .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (06) :931-936

[29] A phase II study of cetuximab (Erbitux®) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer [J].

Koo, Dong Hoe ;

Lee, Jae-Lyun ;

Kim, Tae Won ;

Chang, Heung Moon ;

Ryu, Min-Hoe ;

Lee, Sung Sook ;

Kim, Min Kyoung ;

Sym, Sun Jin ;

Lee, Jung Shin ;

Kang, Yoon-Koo .

JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 :S98-S103

[30] A Multicenter Phase II Clinical Study of Oxaliplatin, Folinic Acid, and 5-Fluorouracil Combination Chemotherapy as Second-Line Treatment for Advanced Colorectal Cancer: A Japanese Experience [J].

Ogata, Yutaka ;

Tokunaga, Shoji ;

Emi, Yasunori ;

Oki, Eiji ;

Saeki, Hiroshi ;

Shirabe, Ken ;

Hasegawa, Hirofumi ;

Sadanaga, Noriaki ;

Samura, Hironori ;

Fujita, Fumihiko ;

Tanaka, Takaho ;

Kitazono, Masaki ;

Yamamoto, Manabu ;

Morikita, Tatsuma ;

Inomata, Masafumi ;

Kakeji, Yoshihiro ;

Shirouzu, Kazuo ;

Maehara, Yoshihiko .

SURGERY TODAY, 2011, 41 (01) :84-90

← 1 2 3 4 5 →